Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Aristolochic acid-associated urothelial cancer in Taiwan.

Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP.

Proc Natl Acad Sci U S A. 2012 May 22;109(21):8241-6. doi: 10.1073/pnas.1119920109.

2.

Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.

Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS.

Int J Cancer. 2013 Jul;133(1):14-20. doi: 10.1002/ijc.28013.

3.

TP53 Mutational signature for aristolochic acid: an environmental carcinogen.

Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelaković B, Wu L, Truong S, Fernandes A, Grollman AP.

Int J Cancer. 2011 Sep 15;129(6):1532-6. doi: 10.1002/ijc.26077.

4.

Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.

Jelaković B, Karanović S, Vuković-Lela I, Miller F, Edwards KL, Nikolić J, Tomić K, Slade N, Brdar B, Turesky RJ, Stipančić Ž, Dittrich D, Grollman AP, Dickman KG.

Kidney Int. 2012 Mar;81(6):559-67. doi: 10.1038/ki.2011.371.

5.

Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.

Hollstein M, Moriya M, Grollman AP, Olivier M.

Mutat Res. 2013 Jul-Sep;753(1):41-9. doi: 10.1016/j.mrrev.2013.02.003. Review.

6.

Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.

Grollman AP.

Environ Mol Mutagen. 2013 Jan;54(1):1-7. doi: 10.1002/em.21756. Review.

PMID:
23238808
7.

Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome.

Schetter AJ, Harris CC.

Proc Natl Acad Sci U S A. 2012 May 22;109(21):7955-6. doi: 10.1073/pnas.1205457109. No abstract available.

8.

Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania.

Schmeiser HH, Kucab JE, Arlt VM, Phillips DH, Hollstein M, Gluhovschi G, Gluhovschi C, Modilca M, Daminescu L, Petrica L, Velciov S.

Environ Mol Mutagen. 2012 Oct;53(8):636-41. doi: 10.1002/em.21732.

PMID:
22987305
9.

Variation in presentation and presence of DNA adducts and p53 mutations in patients with endemic nephropathy--an environmental form of the aristolochic acid nephropathy.

Karanović S, Lela IV, Jelaković B, Dickman KG, Peić AK, Dittrich D, Knežević M, Matijević V, Fernandes AS, Miller F.

Kidney Blood Press Res. 2013;37(1):1-8. doi: 10.1159/000343394.

10.

Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.

Schmeiser HH, Nortier JL, Singh R, Gamboa da Costa G, Sennesael J, Cassuto-Viguier E, Ambrosetti D, Rorive S, Pozdzik A, Phillips DH, Stiborova M, Arlt VM.

Int J Cancer. 2014 Jul 15;135(2):502-7.

PMID:
24921086
11.

Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry.

Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, Bonala R, Johnson F, Dickman KG, Grollman AP, Turesky RJ.

Chem Res Toxicol. 2012 May 21;25(5):1119-31. doi: 10.1021/tx3000889.

12.

Aristolochic acid and the etiology of endemic (Balkan) nephropathy.

Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12129-34.

13.

Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.

Jelaković B, Castells X, Tomić K, Ardin M, Karanović S, Zavadil J.

Int J Cancer. 2015 Jun 15;136(12):2967-72. doi: 10.1002/ijc.29338.

14.

Molecular markers in upper urothelial carcinoma associated to Balkan endemic nephropathy. Aristolochic acid as the major risk factor of the worldwide disease.

Jankovic Velickovic L, Hattori T, Stefanovic V.

ScientificWorldJournal. 2009 Dec 16;9:1360-73. doi: 10.1100/tsw.2009.162.

15.

p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.

Slade N, Moll UM, Brdar B, Zorić A, Jelaković B.

Mutat Res. 2009 Apr 26;663(1-2):1-6. doi: 10.1016/j.mrfmmm.2009.01.005. Review.

16.

Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection.

Aydin S, Dekairelle AF, Ambroise J, Durant JF, Heusterspreute M, Guiot Y, Cosyns JP, Gala JL.

PLoS One. 2014 Sep 3;9(9):e106301. doi: 10.1371/journal.pone.0106301.

17.

Urothelial malignant disease and Chinese herbal nephropathy.

Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD.

Lancet. 2001 Nov 3;358(9292):1515-6.

PMID:
11705569
18.

Urothelial lesions in Chinese-herb nephropathy.

Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C.

Am J Kidney Dis. 1999 Jun;33(6):1011-7.

PMID:
10352187
19.

Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.

Arlt VM, Stiborova M, Schmeiser HH.

Mutagenesis. 2002 Jul;17(4):265-77. Review.

20.

Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations.

Xiao J, Zhu X, Hao GY, Zhu YC, Hou HJ, Zhang J, Ma LL, Tian Y, Zhang YH.

Transplant Proc. 2011 Dec;43(10):3751-4. doi: 10.1016/j.transproceed.2011.09.069.

PMID:
22172840
Items per page

Supplemental Content

Support Center